JP2022513630A5 - - Google Patents

Info

Publication number
JP2022513630A5
JP2022513630A5 JP2021529310A JP2021529310A JP2022513630A5 JP 2022513630 A5 JP2022513630 A5 JP 2022513630A5 JP 2021529310 A JP2021529310 A JP 2021529310A JP 2021529310 A JP2021529310 A JP 2021529310A JP 2022513630 A5 JP2022513630 A5 JP 2022513630A5
Authority
JP
Japan
Prior art keywords
cancer
group
dendrimer
assembly unit
dendrimer according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021529310A
Other languages
English (en)
Japanese (ja)
Other versions
JP7541978B2 (ja
JP2022513630A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2019/051312 external-priority patent/WO2020107078A1/en
Publication of JP2022513630A publication Critical patent/JP2022513630A/ja
Publication of JP2022513630A5 publication Critical patent/JP2022513630A5/ja
Application granted granted Critical
Publication of JP7541978B2 publication Critical patent/JP7541978B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021529310A 2018-11-29 2019-11-29 治療および画像化のためのデンドリマー Active JP7541978B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018904548 2018-11-29
AU2018904548A AU2018904548A0 (en) 2018-11-29 Dendrimer for therapy and imaging
PCT/AU2019/051312 WO2020107078A1 (en) 2018-11-29 2019-11-29 Dendrimer for therapy and imaging

Publications (3)

Publication Number Publication Date
JP2022513630A JP2022513630A (ja) 2022-02-09
JP2022513630A5 true JP2022513630A5 (https=) 2022-12-06
JP7541978B2 JP7541978B2 (ja) 2024-08-29

Family

ID=70852487

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529310A Active JP7541978B2 (ja) 2018-11-29 2019-11-29 治療および画像化のためのデンドリマー

Country Status (12)

Country Link
US (2) US20220023448A1 (https=)
EP (1) EP3886912A4 (https=)
JP (1) JP7541978B2 (https=)
KR (1) KR102940818B1 (https=)
CN (1) CN113164615A (https=)
AU (1) AU2019390489B2 (https=)
BR (1) BR112021008480A2 (https=)
CA (1) CA3120881A1 (https=)
IL (1) IL283511A (https=)
MX (1) MX2021006073A (https=)
SG (1) SG11202104309RA (https=)
WO (1) WO2020107078A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102948775B1 (ko) * 2018-11-20 2026-04-03 스타파마 피티와이 리미티드 치료 덴드리머
EP4034169B1 (en) * 2019-09-26 2026-02-11 Starpharma Pty Limited Therapeutic dendrimer
KR20230065935A (ko) * 2020-06-03 2023-05-12 스타파마 피티와이 리미티드 치료적 접합체
WO2022094327A1 (en) * 2020-10-30 2022-05-05 Ashvattha Therapeutics, Inc. Radiolabeled ether dendrimer conjugates for pet imaging and radiotherapy
WO2024007034A2 (en) * 2022-07-01 2024-01-04 The Johns Hopkins University Dendrimer-delivered alpha-particle radiotherapy for treatment of glioblastoma and other cancers in the brain
CN117088825A (zh) * 2023-10-12 2023-11-21 成都威斯津生物医药科技有限公司 一种可离子化脂质、含该可离子化脂质的药物组合物及其用途
WO2025222234A1 (en) * 2024-04-24 2025-10-30 Starpharma Pty Ltd Targeted dendrimer conjugates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5989294B2 (ja) * 2006-01-20 2016-09-07 スターファーマ・プロプライエタリー・リミテッドＳｔａｒｐｈａｒｍａ Ｐｔｙ Ｌｔｄ 修飾高分子
WO2008017122A1 (en) * 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
CA2770980A1 (en) * 2009-07-15 2011-01-20 Roger Y. Tsien Peptides whose uptake in cells is controllable
US9011816B2 (en) * 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
IN2014DN00101A (https=) * 2011-06-06 2015-05-15 Starpharma Pty Ltd
US20180326081A1 (en) * 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
US9642916B2 (en) * 2012-12-12 2017-05-09 The Regents Of The University Of California Porphyrin modified telodendrimers
US10898594B2 (en) * 2015-10-27 2021-01-26 The Johns Hopkins University PAMAM dendrimer based CEST imaging agents and uses thereof
CN107349439A (zh) * 2017-07-21 2017-11-17 广州军区广州总医院 一种正电子标记纳米探针及其制备方法与用途
BR112022003628A2 (pt) * 2019-08-28 2022-05-24 Starpharma Pty Ltd Conjugados de dendrímero direcionado

Similar Documents

Publication Publication Date Title
JP2022513630A5 (https=)
JP2025066807A (ja) 生体直交型組成物
US9687572B2 (en) PSMA-targeted dendrimers
US11801307B2 (en) Antibody-polymer-drug conjugates
MXPA02007820A (es) Composiciones y metodos para aumentar la entrega de drogas a traves de membranas y tejidos biologicos.
JP7541978B2 (ja) 治療および画像化のためのデンドリマー
AU2001236920A1 (en) Compositions and methods for enhancing drug delivery across biological membranes and tissues
JP2023529640A5 (https=)
JP2011521897A5 (https=)
JP6944720B2 (ja) リジン−尿素−グルタメートファーマコフォアを含む修飾デキストラン複合体
US20190388569A1 (en) Multifunctional chelators, complexes, and compositions thereof, and methods of using same
US20240293588A1 (en) Therapeutic conjugates
CN121100004A (zh) 具有改进的t-连接子的反式-环辛烯
JP2009527559A (ja) 二官能性レソルシノール、チオレソルシノールおよびジチオレソルシノール誘導体金属キレート形成性結合体
EP2583966A2 (en) Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases
AU2023221765B2 (en) Masked il12 protein
Thakur et al. Improved antibody targeting with interferon-α-2b conjugate
Berger Toward Fullerene Immunotherapy with Water-Soluble Paclitaxel-Fullerene Conjugates